SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 197 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 1.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $2,740,000 | -31.6% | 218,698 | -14.8% | 0.00% | -33.3% |
Q4 2020 | $4,008,000 | +76.6% | 256,826 | +7.0% | 0.00% | +50.0% |
Q3 2020 | $2,269,000 | +8.7% | 240,100 | +3.0% | 0.00% | 0.0% |
Q2 2020 | $2,088,000 | +39.9% | 233,000 | -0.5% | 0.00% | 0.0% |
Q1 2020 | $1,492,000 | -25.4% | 234,200 | -2.0% | 0.00% | 0.0% |
Q4 2019 | $2,000,000 | +15.4% | 239,000 | +24.8% | 0.00% | 0.0% |
Q3 2019 | $1,733,000 | +44.1% | 191,500 | +71.4% | 0.00% | +100.0% |
Q2 2019 | $1,203,000 | -2.3% | 111,700 | -13.4% | 0.00% | -50.0% |
Q1 2019 | $1,231,000 | -18.9% | 129,030 | -2.4% | 0.00% | 0.0% |
Q4 2018 | $1,518,000 | -14.7% | 132,230 | +25.9% | 0.00% | 0.0% |
Q3 2018 | $1,780,000 | +11.8% | 105,030 | -6.3% | 0.00% | 0.0% |
Q2 2018 | $1,592,000 | -38.0% | 112,130 | -17.0% | 0.00% | -50.0% |
Q1 2018 | $2,566,000 | +4.9% | 135,062 | -9.5% | 0.00% | +33.3% |
Q4 2017 | $2,447,000 | +42.7% | 149,235 | +30.6% | 0.00% | 0.0% |
Q3 2017 | $1,715,000 | +70.5% | 114,300 | 0.0% | 0.00% | +50.0% |
Q2 2017 | $1,006,000 | +69.4% | 114,300 | 0.0% | 0.00% | +100.0% |
Q1 2017 | $594,000 | +63.2% | 114,300 | -4.2% | 0.00% | 0.0% |
Q4 2016 | $364,000 | -34.1% | 119,300 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $552,000 | -25.2% | 119,300 | -6.4% | 0.00% | 0.0% |
Q2 2016 | $738,000 | -7.3% | 127,500 | -3.0% | 0.00% | 0.0% |
Q1 2016 | $796,000 | -37.5% | 131,500 | -5.7% | 0.00% | -50.0% |
Q4 2015 | $1,274,000 | +61.9% | 139,500 | 0.0% | 0.00% | +100.0% |
Q3 2015 | $787,000 | -49.1% | 139,500 | 0.0% | 0.00% | -50.0% |
Q2 2015 | $1,547,000 | -19.6% | 139,500 | 0.0% | 0.00% | -33.3% |
Q1 2015 | $1,924,000 | 0.0% | 139,500 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $1,924,000 | +27.8% | 139,500 | 0.0% | 0.00% | +50.0% |
Q3 2014 | $1,505,000 | -39.1% | 139,500 | -13.8% | 0.00% | -33.3% |
Q2 2014 | $2,472,000 | +3.5% | 161,858 | +5.2% | 0.00% | 0.0% |
Q1 2014 | $2,389,000 | +21.1% | 153,793 | +10.2% | 0.00% | 0.0% |
Q4 2013 | $1,973,000 | +32.9% | 139,500 | -1.6% | 0.00% | 0.0% |
Q3 2013 | $1,485,000 | +52.0% | 141,740 | +13.3% | 0.00% | +50.0% |
Q2 2013 | $977,000 | – | 125,140 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alexandria Capital, LLC | 916,153 | $8,740,000 | 1.27% |
Casdin Capital, LLC | 1,080,000 | $10,303,000 | 1.13% |
Rhenman & Partners Asset Management AB | 843,957 | $8,051,000 | 0.94% |
WASATCH ADVISORS LP | 6,437,908 | $61,418,000 | 0.67% |
BB BIOTECH AG | 2,650,000 | $25,281,000 | 0.64% |
Trellus Management Company, LLC | 30,000 | $286,000 | 0.54% |
Opus Point Partners Management, LLC | 33,529 | $320,000 | 0.43% |
SECTOR GAMMA AS | 238,857 | $2,279,000 | 0.36% |
Leisure Capital Management | 37,656 | $359,000 | 0.30% |
Ceeto Capital Group, LLC | 41,000 | $391,000 | 0.29% |